1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1640
  5. Art Unit 1641
  6. Examiner Rooney

Examiner Rooney Nora M

1641-ROONEY-NORA-M

Employment Information

Art Unit:1641 — Drug, bio-affecting and body treating compositions
Group:1640 — Immunology including antibodies, B&T lymphocytes, antigen presenting cells and Gram-positive/Negative Bacteria, Parasitic and Fungal Immunology
Classes: 424 — Drug, bio-affecting and body treating compositions
435 — Chemistry: molecular biology and microbiology
530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
506 — Combinatorial chemistry technology: method, library, apparatus
436 — Chemistry: analytical and immunological testing
Phone:(571) 272-9937
Email:nora.rooney@uspto.gov
Location:VA 22314
Title:Pat Examnr Biolgy
Service:20 years
Grade:GS-14

Grant Rate and Difficulty Ranking

73
3-Year Grant rate: 59% over 253 cases
Difficulty: Harder
Difficulty Percentile: 73rd

With Examiner Rooney, you have a 59% chance of getting an issued patent by 3 years after the first office action. Examiner Rooney is a harder examiner and in the 73rd percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Rooney, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1641

Examiner Rooney's grant rate is higher than that of Art Unit 1641 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Rooney 1.8
Art Unit 1641 1.8

Interview Benefit

Grant Rate without Interview

Examiner Rooney has granted 115 of 209 cases without any applicant-requested interviews for a grant rate of 55%.

Grant Rate with Interview

Examiner Rooney has granted 34 of 44 cases with at least one applicant-requested interview for a grant rate of 77%.

Interview Benefit

With Examiner Rooney, conducting an interview increases your chance of getting a patent granted by 40%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
18545795 Methods Of Treating Allergy Using Anti-Bet V 1 Antibodies Rejection information available with a Premium Stats subscription. See our pricing. Patented View
17813985 Therapeutic Interferon Alpha 1 Proteins Patented View
18025985 Pharmaceutical Composition For Allergen Specific Immunotherapy Abandoned View
18457553 Agonistic Anti-Il-2r Antibodies And Methods Of Use Patented View
18192861 Complex-Specific Antibodies And Antibody Fragments And Its Use Patented View
18176678 Peptides And Combination Of Peptides Of Non-Canonical Origin For Use In Immunotherapy Against Different Types Of Cancers Abandoned View
17800837 Method For Treating Asthma Or Allergic Disease Abandoned View
17795075 Method For Producing Composition Containing Polypeptide With Suppressed Coloring Patented View
17394506 Administration Of Vaccines To Sites Of Temporally Induced Cell-Mediated Hypersensitivity Reactions, To Facilitate The Development Of Protective Sensitization Against Infectious Diseases And Cancers Abandoned View
17604964 Method For Separation Of Antibodies Or Antibody Fragments Being Devoid Of An Fc Region Capable Of Binding To Protein A Patented View
17536667 Peptides, Reagents And Methods For Detecting Food Allergy Patented View
18176084 Anti-B7-H4 Antibodies And Methods Abandoned View
18491287 Fish Allergy Antigen Patented View
18329443 Treatment Of Ige-Mediated Diseases With Antibodies That Specifically Bind Cd38 Patented View
16891208 Compositions For Immunotherapy Patented View
17933185 Modifying Binding Molecules To Minimize Pre-Exisiting Interactions Patented View
16489970 Modified Ck And Ch1 Domains Abandoned View
17422222 Methods Of Introducing Food Allergens Abandoned View
18609108 Multispecific Binding Constructs Against Checkpoint Molecules And Uses Thereof Patented View
18344391 Autoimmune Suppressor And Application Thereof Patented View
17595193 Systemic Allergic Response Risk Assessment In Peanut Oral Immunotherapy Abandoned View
17813578 Anti-Gal3 Antibodies And Uses Thereof Patented View
17607985 Method For Selecting Biological Binding Molecules Abandoned View
17313738 Reduction Of Viral Disease Transmission By Avian Antibodies Abandoned View
17936739 Methods Of Treatment Using A Veterinary Mite Allergen Extract Abandoned View
18462987 Soybean Allergy Antigen Patented View
16542198 Peanut Oral Immunotherapy With Maintenance Dose Patented View
17063589 Composition For The Treatment Of Type I Allergic Hypersensitivities By Immune Desensitization Through Slit Immunotherapy With Unadulterated Allergen, Vitamin A, Vitamin D And An Immuno-Effective Amount Of Adjuvant Of Essential Oils Abandoned View
17048073 Antibodies For Chelated Radionuclides Abandoned View
17478310 Mixed Allergen Compositions And Methods For Using The Same Abandoned View
17285884 Rapid Cell Isolation And Recovery Using Hollow Glass Microspheres Coated With Biodegradable Nanostructured Films Patented View
18376135 Nanoemulsion Compositions For Preventing, Suppressing Or Eliminating Allergic And Inflammatory Disease Patented View
17714507 Anti-Allergen Antibodies Patented View
17053784 Lamp Constructs Comprising Allergens Patented View
18244038 Composition And Method For Reducing Allergic Response Abandoned View
18335995 Trivalent Trispecific Antibody Constructs Abandoned View
17996114 Dosage Units And Regimen, Uses, Methods Or Formulations Of Compositions Comprising A Recombinant Protein Comprising Interleukin-12 And An Antibody Binding The Extra-Domain B Of Fibronectin Abandoned View
18977144 Novel Antigen Binding Molecule Formats Patented View
17168350 Assays For Detecting Peanut Allergies Abandoned View
17891757 Mixed Allergen Compositions And Methods For Using The Same Abandoned View
18469961 Hla Binding Vaccine Moieties And Uses Thereof Patented View
17752639 Methods Of Oral Immunotherapy Patented View
17500794 Antibodies To Oxidation-Specific Epitopes Patented View
17601628 Combination Of Synthetic Peptides With Affinity To The Tgf-SS Receptor And With Affinity To The Il-10 Receptor, Pharmaceutical Composition And Their Use As Immunomodulators In The Treatment Of Autoimmune, Inflammatory Or Allergic Diseases Abandoned View
18664070 Binding Agents Targeting Trop2-Expressing Tumor Cells Patented View
18640981 Novel Antigen Binding Molecule Formats Patented View
17432705 Modified Fc Fragment, Antibody Comprising Same, And Application Thereof Patented View
17282781 Her2-Binding Tetrameric Polypeptides Abandoned View
16980607 Metabolic Enzyme Activity And Disulfide Bond Reduction During Protein Production Patented View
16417946 Peptides And Methods For Detecting Peanut Allergies Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.